Collegium Pharmaceutical, Inc. announced it will present nine posters showcasing real-world data from its differentiated pain portfolio at PAINWeek 2025. The annual meeting is scheduled to take place in Las Vegas, NV, from September 2-5, 2025. These presentations reflect Collegium’s ongoing commitment to responsible pain management.
Thomas Smith, M.D., Chief Medical Officer, stated that this new research will provide healthcare professionals with real-world insights to support clinical decision-making. The company believes that ongoing research and data transparency are essential to advancing pain care in a meaningful way. The poster session is scheduled for Thursday, September 4.
The data will highlight the value of Collegium's pain treatments, including products like BELBUCA and XTAMPZA ER. This initiative reinforces the company's position in the pain care community and its dedication to providing differentiated medicines.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.